226 related articles for article (PubMed ID: 28315663)
1. Enhancing the Catalytic Deamination Activity of APOBEC3C Is Insufficient to Inhibit Vif-Deficient HIV-1.
Jaguva Vasudevan AA; Hofmann H; Willbold D; Häussinger D; Koenig BW; Münk C
J Mol Biol; 2017 Apr; 429(8):1171-1191. PubMed ID: 28315663
[TBL] [Abstract][Full Text] [Related]
2. Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.
Zhang Z; Gu Q; Jaguva Vasudevan AA; Jeyaraj M; Schmidt S; Zielonka J; Perković M; Heckel JO; Cichutek K; Häussinger D; Smits SHJ; Münk C
J Virol; 2016 Nov; 90(22):10193-10208. PubMed ID: 27581978
[TBL] [Abstract][Full Text] [Related]
3. Loop 1 of APOBEC3C Regulates its Antiviral Activity against HIV-1.
Jaguva Vasudevan AA; Balakrishnan K; Gertzen CGW; Borvető F; Zhang Z; Sangwiman A; Held U; Küstermann C; Banerjee S; Schumann GG; Häussinger D; Bravo IG; Gohlke H; Münk C
J Mol Biol; 2020 Nov; 432(23):6200-6227. PubMed ID: 33068636
[TBL] [Abstract][Full Text] [Related]
4. APOBEC3C Tandem Domain Proteins Create Super Restriction Factors against HIV-1.
McDonnell MM; Crawford KHD; Dingens AS; Bloom JD; Emerman M
mBio; 2020 Apr; 11(2):. PubMed ID: 32345636
[TBL] [Abstract][Full Text] [Related]
5. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.
Pery E; Rajendran KS; Brazier AJ; Gabuzda D
J Virol; 2009 Mar; 83(5):2374-81. PubMed ID: 19109396
[TBL] [Abstract][Full Text] [Related]
6. Natural APOBEC3C variants can elicit differential HIV-1 restriction activity.
Anderson BD; Ikeda T; Moghadasi SA; Martin AS; Brown WL; Harris RS
Retrovirology; 2018 Dec; 15(1):78. PubMed ID: 30558640
[TBL] [Abstract][Full Text] [Related]
7. Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases.
Zhang W; Huang M; Wang T; Tan L; Tian C; Yu X; Kong W; Yu XF
Cell Microbiol; 2008 Aug; 10(8):1662-75. PubMed ID: 18419775
[TBL] [Abstract][Full Text] [Related]
8. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
Wang J; Shaban NM; Land AM; Brown WL; Harris RS
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
[TBL] [Abstract][Full Text] [Related]
9. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.
Yu Q; Chen D; König R; Mariani R; Unutmaz D; Landau NR
J Biol Chem; 2004 Dec; 279(51):53379-86. PubMed ID: 15466872
[TBL] [Abstract][Full Text] [Related]
10. Cytidine deaminase efficiency of the lentiviral viral restriction factor APOBEC3C correlates with dimerization.
Adolph MB; Ara A; Feng Y; Wittkopp CJ; Emerman M; Fraser JS; Chelico L
Nucleic Acids Res; 2017 Apr; 45(6):3378-3394. PubMed ID: 28158858
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
Feng Y; Love RP; Chelico L
J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
[TBL] [Abstract][Full Text] [Related]
12. The APOBEC3C crystal structure and the interface for HIV-1 Vif binding.
Kitamura S; Ode H; Nakashima M; Imahashi M; Naganawa Y; Kurosawa T; Yokomaku Y; Yamane T; Watanabe N; Suzuki A; Sugiura W; Iwatani Y
Nat Struct Mol Biol; 2012 Oct; 19(10):1005-10. PubMed ID: 23001005
[TBL] [Abstract][Full Text] [Related]
13. Structural Insights into HIV-1 Vif-APOBEC3F Interaction.
Nakashima M; Ode H; Kawamura T; Kitamura S; Naganawa Y; Awazu H; Tsuzuki S; Matsuoka K; Nemoto M; Hachiya A; Sugiura W; Yokomaku Y; Watanabe N; Iwatani Y
J Virol; 2016 Jan; 90(2):1034-47. PubMed ID: 26537685
[TBL] [Abstract][Full Text] [Related]
14. Identification of a Conserved Interface of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Vifs with Cullin 5.
Gu Q; Zhang Z; Gertzen CGW; Häussinger D; Gohlke H; Münk C
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263270
[TBL] [Abstract][Full Text] [Related]
15. Model structure of APOBEC3C reveals a binding pocket modulating ribonucleic acid interaction required for encapsidation.
Stauch B; Hofmann H; Perkovic M; Weisel M; Kopietz F; Cichutek K; Münk C; Schneider G
Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12079-84. PubMed ID: 19581596
[TBL] [Abstract][Full Text] [Related]
16. Divergence in Dimerization and Activity of Primate APOBEC3C.
Gaba A; Hix MA; Suhail S; Flath B; Boysan B; Williams DR; Pelletier T; Emerman M; Morcos F; Cisneros GA; Chelico L
J Mol Biol; 2021 Dec; 433(24):167306. PubMed ID: 34666043
[TBL] [Abstract][Full Text] [Related]
17. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.
Henriet S; Mercenne G; Bernacchi S; Paillart JC; Marquet R
Microbiol Mol Biol Rev; 2009 Jun; 73(2):211-32. PubMed ID: 19487726
[TBL] [Abstract][Full Text] [Related]
18. Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1.
Bourara K; Liegler TJ; Grant RM
PLoS Pathog; 2007 Oct; 3(10):1477-85. PubMed ID: 17967058
[TBL] [Abstract][Full Text] [Related]
19. Dissecting APOBEC3G substrate specificity by nucleoside analog interference.
Rausch JW; Chelico L; Goodman MF; Le Grice SF
J Biol Chem; 2009 Mar; 284(11):7047-58. PubMed ID: 19136562
[TBL] [Abstract][Full Text] [Related]
20. APOBEC3B Potently Restricts HIV-2 but Not HIV-1 in a Vif-Dependent Manner.
Bandarra S; Miyagi E; Ribeiro AC; Gonçalves J; Strebel K; Barahona I
J Virol; 2021 Nov; 95(23):e0117021. PubMed ID: 34523960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
